Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this investigational study is to determine if a study medication is safe and effective in reducing the symptoms associated with endometriosis; if the study medication reduces the need for pain medication for endometriosis symptoms; and if the study medication improves a participant's ability to carry out daily activities. Qualified participants will receive no cost treatment, which may include study-related examinations, diagnostic procedures including a Pap smear, laboratory testing, and a mammogram (aged 40-45). Qualified participants will also receive study medication at no cost. As a participant, the study volunteer may also experience the satisfaction of knowing she is helping the advancement of women's health care.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Surgical diagnosis of endometriosis within 5 years

• Not pregnant and not lactating

• Willing to use non-hormonal contraception, history of regular menstrual cycles

Exclusion Criteria:

• Hysterectomy, surgical treatment for endometriosis within 3 months

• Certain medications for the treatment of endometriosis

• Previous history of a malignancy

• Abnormalities on physical or gyn exams and abnormal lab tests